Clincosm LogoSign in Get a demo

RNA-seq Analysis of PBMC in Patients With OPLL

Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04963101
Collaborator
(none)
30
Enrollment
1
Location
12.2
Anticipated Duration (Months)
2.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study, we planned to identify transcriptome expression profiles (circRNAs, lncRNAs, and mRNAs) from peripheral blood mononuclear cells (PBMCs) of 30 patients with OPLL and 30 other non-OPLL patients by high-throughput sequencing.Sequence analysis was used to predict miRNAs that might bind circRNAs and lncRNAs.Through bioinformatics analysis, competitive endogenous RNAs (cerRNAs), as well as coexpression networks among circRNAs, lncRNAs, miRNAs, and mRNAs, were constructed to provide key molecules and signaling pathways associated with OPLL.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Characteristics of Transcriptome Expression Profile of PBMCs in Patients With Ossification of the Posterior Longitudinal Ligament
    Actual Study Start Date :
    Jun 25, 2021
    Anticipated Primary Completion Date :
    Jun 25, 2022
    Anticipated Study Completion Date :
    Jun 30, 2022

    Outcome Measures

    Primary Outcome Measures

    1. circRNA, lncRNA, mRNA [1 year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    1. Voluntarily participate in the clinical study and sign the informed consent;

    2. All OPLL patients meet the diagnostic criteria set out in the JOA Clinical Practice Guidelines for Spinal Ligament Osification 2019;

    3. Age ≥18, gender unlimited;

    4. All non-OPLL patients and healthy volunteers have no serious diseases of the heart, lung, brain, liver, kidney and blood system, such as autoimmune diseases, tumors, psychosis, infectious diseases, etc., and have no bad habits or recent history of taking special drugs.

    Exclusion Criteria:

    1. Unable to sign the informed consent;

    2. Patients who do not meet the inclusion criteria or diagnostic criteria;

    3. <18 years old;

    4. Women planning to become pregnant/lactating/pregnant;

    5. Complicated with serious heart, lung, brain, liver, kidney, blood system diseases, such as autoimmune diseases, tumors, mental illness, infectious diseases, drug addiction and other bad addicts;Those who have recently taken special drugs;

    6. Individuals who do not agree to donate peripheral blood or who are obviously uncomfortable with drawing blood.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Facility Zhuhai Guangdong China

    Sponsors and Collaborators

    • Fifth Affiliated Hospital, Sun Yat-Sen University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Huading Lu, Director of orthopaedics, Fifth Affiliated Hospital, Sun Yat-Sen University
    ClinicalTrials.gov Identifier:
    NCT04963101
    Other Study ID Numbers:
    • ZDWY.CSYGJWK.003
    First Posted:
    Jul 15, 2021
    Last Update Posted:
    Jul 15, 2021
    Last Verified:
    Jul 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jul 15, 2021